Entera Bio’s oversubscribed private placement brings specialist healthcare investors onto its shareholder register and provides funding through 2030. The capital is expected to support the Phase 3 development and regulatory filing for oral osteoporosis candidate EB613, while advancing EB612 in hypoparathyroidism. The transaction materially strengthens the company’s financing position but introduces substantial shareholder dilution and greater board influence for BVF Partners.

Key Highlights

  • Entera Bio (NASDAQ: ENTX) priced an oversubscribed private placement with gross proceeds of approximately $275 million.
  • The transaction includes about 122.96 million ordinary shares and 11.84 million pre-funded warrants priced at $2.04 each.
  • Proceeds are expected to finance the Phase 3 programme and subsequent New Drug Application for EB613.
  • Funding will also support the Phase 1 development of EB612, being advanced with OPKO Health (NASDAQ: OPK).
  • The financing extends Entera Bio’s expected cash runway through 2030 and gives BVF Partners the right to appoint two directors.

Entera Bio Financing Strengthens Clinical Funding Position

Entera Bio (NASDAQ: ENTX) has secured a substantial funding commitment at a pivotal stage in its transition from clinical development towards potential commercialisation. The participation of BVF Partners, RA Capital and Perceptive Advisors brings specialist life-sciences investors into the financing and indicates institutional interest in the company’s oral peptide-delivery platform.

The placement involves approximately 122.96 million ordinary shares and 11.84 million pre-funded warrants, each priced at $2.04. The scale of the issuance materially expands the company’s equity base. While this reduces near-term financing uncertainty, it also creates significant dilution for existing shareholders and increases the importance of disciplined clinical execution.

EB613 Phase 3 Osteoporosis Programme Receives Full Funding

The principal use of proceeds is the Phase 3 programme for EB613, Entera Bio’s (NASDAQ: ENTX) oral parathyroid hormone candidate for osteoporosis. The financing is also intended to cover preparation and submission of a New Drug Application, subject to successful clinical outcomes and regulatory requirements.

EB613 seeks to offer an oral alternative within an osteoporosis market where injectable anabolic treatments can face adherence and accessibility limitations. Its competitive position will depend on Phase 3 efficacy, safety, patient adherence and the requirements established through regulatory engagement.

EB612 Partnership Adds Pipeline Diversification

Part of the proceeds will support a Phase 1 trial of EB612 for hypoparathyroidism. The candidate is being developed alongside OPKO Health (NASDAQ: OPK) and applies Entera Bio’s oral-delivery technology to another endocrine disorder commonly managed through long-term therapy.

This programme broadens the clinical pipeline beyond osteoporosis, although it remains at an earlier stage and carries the development risks typical of Phase 1 assets.

Cash Runway Extends Through 2030

The financing is expected to extend Entera Bio’s (NASDAQ: ENTX) cash runway through 2030, giving the company greater capacity to conduct late-stage trials without relying on immediate follow-on capital. BVF Partners’ right to appoint two board members also introduces a meaningful governance change, increasing the investor’s influence over strategic oversight as the company advances EB613.